SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biomea Fusion, Inc.

NEW YORK, June 7, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors in Biomea Fusion, Inc. (“Biomea” or the “Company”) (NASDAQ: BMEA). Such investors are advised to contact Danielle Peyton at (email protected) or 646-581-9980, extension 7980.

The investigation concerns whether Biomea and certain of its officers and/or directors engaged in securities transactions. Fraud or other unlawful business practices.

(Click here for information on joining the class action lawsuit.)

At June 6, 2024Biomea issued a press release announcing that the company had received notice from the U.S. Food and Drug Administration (FDA) that Biomea’s ongoing Phase I/II clinical trials of its investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112) had been placed on full hold. The press release stated that “the FDA cited deficiencies due to the magnitude of potential drug-induced liver toxicity observed in the completed dose-escalation phase of COVALENT-111.”

Following this news, Biomea’s share price fell 7,13 € per share or 63.27%, and closed at $4.14 per share on June 7, 2024.

Pomerantz LLP, with offices in new York, Chicago, Los Angeles, London, ParisAnd Tel-Avivis considered one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. PomerantzKnown as the dean of class action lawyers, Pomerantz was a pioneer in the field of securities class action litigation. Today, more than 85 years later, Pomerantz continues the tradition he established and fights for the rights of securities litigation victims. FraudBreach of fiduciary duty and corporate misconduct. The firm has won billions of dollars in damages on behalf of class action plaintiffs. See www.pomlaw.com.

Attorney advertising. Past results do not guarantee similar results.

CONTACT:
Danielle Peyton
Pomerantz LLP
(email protected)
646-581-9980 extension 7980

Never miss a story from Pomerantz LLP again.